Actinogenic Medical continues to make progress with its 36-week Xanamia phase IIB/III study that assesses xanamem in patients with biomarker-positive mild-to-the-time Alzheimer’s disease (AD). The company recently announced that it has randomized and treated 40 patients (out of 220 goals). Actinogen now expects to report interim (24-week) results from the first 100 patients in Q4 CY25 (vs Q3 Cy25 earlier), which can be a material catalyst and support licensing and/or value realization. Full study results are controlled for H2 CY26. Our risk-adjusted net-current value is $ 673.8 million (compared to $ 619.8 million earlier).The diligent article Lesen …